Edith A. Perez, MD, deputy director, Mayo Clinic Cancer Center, Florida, director, Breast Program, Serene M. and Frances C. Durling Professor of Medicine, Mayo Medical School, discusses the antibody-drug conjugate T-DM1 that is being investigated as a treatment for patients with HER2-positive, unresectable, locally advanced or metastatic breast cancer.

For more information on breast cancer treatments, visit [ Ссылка ]

свернуть